8-K: Coherus BioSciences to Divest UDENYCA Franchise to Intas Pharmaceuticals for up to $558 Million

Coherus BioSciences will divest its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, allowing Coherus to focus on its immuno-oncology pipeline.

Summary

• Coherus BioSciences has agreed to sell its UDENYCA franchise to Intas Pharmaceuticals for a total consideration of up to $558.4 million.
• The deal includes an upfront payment of $483.4 million, which is subject to adjustment based on the final inventory valuation.
• Coherus is also eligible to receive two additional payments of $37.5 million each if UDENYCA achieves certain net sales milestones.
• The first milestone payment is triggered if net sales reach $300 million in four consecutive fiscal quarters within the first five full fiscal quarters after closing.
• The second milestone payment is triggered if net sales reach $350 million in four consecutive fiscal quarters within the first seven full fiscal quarters after closing.
• The transaction is expected to close in the first quarter of 2025, pending shareholder approval and regulatory clearances.
• Coherus plans to use the proceeds to repay $230 million in convertible notes due in April 2026 and $49.1 million to buy out royalty obligations related to UDENYCA.
• The company anticipates significant cost savings from reduced debt, employee transfers, and eliminated overhead related to UDENYCA.

Sentiment

Score: 8

Explanation: The document is positive overall, highlighting a strategic divestiture that strengthens the company's financial position and allows it to focus on its innovative pipeline. The financial terms are favorable, and the company has a clear plan for the use of proceeds. However, there are risks associated with the transaction and the company's future performance.

Positives

• The divestiture allows Coherus to focus on its innovative immuno-oncology pipeline.
• The transaction will significantly improve Coherus's capital structure by paying off convertible notes.
• Coherus expects substantial cost savings from reduced debt and operational expenses.
• The company will use tax attributes to offset most of the U.S. federal income taxes related to the divestiture.
• The deal provides a cash runway of over two years, past key data readouts expected in 2026.

Negatives

• The transaction is subject to customary closing conditions, including shareholder and regulatory approvals, which could delay or prevent the deal from closing.
• The company is relying on achieving net sales milestones to receive the full $558.4 million, which is not guaranteed.
• The company will lose the revenue stream from the UDENYCA franchise.

Risks

• The transaction may not close in the expected timeframe or at all due to regulatory or shareholder issues.
• There is a risk of competing offers from third parties.
• The company may not realize the anticipated benefits of the transaction.
• The transaction could disrupt current plans and operations.
• There are uncertainties regarding the long-term value of the company's common stock.
• The company faces potential litigation related to the transaction.

Future Outlook

Coherus will focus on its immuno-oncology portfolio, including LOQTORZI, casdozokitug, and CHS-114, with plans to initiate new clinical trials and partnerships. The company expects a cash runway of over two years, past key data readouts expected in 2026.

Management Comments

• Denny Lanfear, Coherus Chairman and Chief Executive Officer, stated that the divestiture allows the company to focus on its innovative immuno-oncology portfolio and strengthen its financial position.
• He also mentioned that the transaction allows Coherus to monetize the value of the UDENYCA franchise to maximize the opportunity for LOQTORZI and advance the development of the I-O pipeline.

Industry Context

This divestiture reflects a trend in the biopharmaceutical industry where companies are focusing on core therapeutic areas and divesting non-core assets to improve financial stability and focus on innovative pipelines. Coherus is shifting its focus from biosimilars to innovative immuno-oncology therapies, which is a high-growth area in the pharmaceutical sector.

Comparison to Industry Standards

• The divestiture of a non-core asset for a significant upfront payment and potential milestone payments is a common strategy in the biopharmaceutical industry to raise capital and focus on core competencies.
• The valuation of the UDENYCA franchise at up to $558.4 million is within the range of similar transactions for established biosimilar products.
• The use of proceeds to pay down debt and buy out royalty obligations is a typical approach to improve financial health and reduce future liabilities.
• The focus on immuno-oncology is consistent with the industry trend towards developing innovative cancer therapies, with companies like Bristol Myers Squibb, Merck, and Roche also heavily investing in this area.
• The development of combination therapies, such as LOQTORZI with casdozokitug and CHS-114, is a common strategy to enhance efficacy and expand the market for cancer treatments, similar to approaches taken by other companies in the sector.

Stakeholder Impact

• Shareholders will benefit from the improved financial position and focus on innovative therapies.
• Employees may be affected by the transfer of certain positions to Intas.
• Customers will see a change in ownership of the UDENYCA franchise.
• Suppliers may experience changes in their relationship with Coherus.

Next Steps

• Coherus will file a proxy statement with the SEC and mail it to shareholders for approval of the divestiture.
• The company will work to obtain regulatory approvals, including from the Hart-Scott-Rodino Antitrust Improvements Act and CFIUS.
• Coherus will initiate a process to fully repay its convertible notes.
• The company will continue to advance its immuno-oncology pipeline, including clinical trials for casdozokitug and CHS-114.
• Coherus plans to provide an updated Q4 2024 sales projection and Q1 2025 cash projection in early January 2025.

Key Dates

Keywords

UDENYCA, Coherus BioSciences, Intas Pharmaceuticals, divestiture, immuno-oncology, LOQTORZI, casdozokitug, CHS-114, asset purchase agreement, milestone payments, convertible notes, biosimilar, oncology